Although activation of EGFR signalling has been reported in CCA patients, EGFR inhibitors such as erlotinib, cetuximab, and panitumumab–as monotherapy or in combination with systemic chemotherapy–reported no OS advantage in several randomized clinical trials, with this lack of benefit also confirmed by some recent meta-analyses [77,78]. Here, EGFR is linked to cholangiocarcinoma.